NO2794666T3 - - Google Patents

Info

Publication number
NO2794666T3
NO2794666T3 NO12859384A NO12859384A NO2794666T3 NO 2794666 T3 NO2794666 T3 NO 2794666T3 NO 12859384 A NO12859384 A NO 12859384A NO 12859384 A NO12859384 A NO 12859384A NO 2794666 T3 NO2794666 T3 NO 2794666T3
Authority
NO
Norway
Application number
NO12859384A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2794666T3 publication Critical patent/NO2794666T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO12859384A 2011-12-19 2012-12-19 NO2794666T3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2011/051538 WO2013095215A1 (fr) 2011-12-19 2011-12-19 Héparines anticoagulantes de faible poids moléculaire
PCT/SE2012/051429 WO2013095277A1 (fr) 2011-12-19 2012-12-19 Utilisation de dérivés d'héparine chimiquement modifiés dans la drépanocytose

Publications (1)

Publication Number Publication Date
NO2794666T3 true NO2794666T3 (fr) 2018-07-21

Family

ID=48668926

Family Applications (2)

Application Number Title Priority Date Filing Date
NO12859384A NO2794666T3 (fr) 2011-12-19 2012-12-19
NO12860938A NO2794667T3 (fr) 2011-12-19 2012-12-19

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO12860938A NO2794667T3 (fr) 2011-12-19 2012-12-19

Country Status (26)

Country Link
US (2) US9480702B2 (fr)
EP (2) EP2794666B1 (fr)
JP (2) JP6703806B2 (fr)
CN (1) CN104053675B (fr)
AU (1) AU2012354226B2 (fr)
BR (1) BR112014014673B1 (fr)
CA (2) CA2856918C (fr)
CY (2) CY1120194T1 (fr)
DK (2) DK2794667T3 (fr)
ES (2) ES2668273T3 (fr)
HR (2) HRP20180726T1 (fr)
HU (2) HUE037555T2 (fr)
IL (1) IL232903A (fr)
IN (1) IN2014MN01056A (fr)
MX (1) MX358439B (fr)
MY (1) MY170069A (fr)
NO (2) NO2794666T3 (fr)
PH (1) PH12014501387A1 (fr)
PL (2) PL2794666T3 (fr)
PT (2) PT2794667T (fr)
RS (2) RS57213B1 (fr)
SI (2) SI2794667T1 (fr)
SM (2) SMT201800217T1 (fr)
TN (2) TN2014000236A1 (fr)
WO (3) WO2013095215A1 (fr)
ZA (1) ZA201403654B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2856492C (fr) 2011-12-19 2017-01-10 Dilafor Ab Nouveau glycosaminoglycan faiblement anticoagulant
WO2013095215A1 (fr) 2011-12-19 2013-06-27 Dilaforette Ab Héparines anticoagulantes de faible poids moléculaire
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
EP2965764A1 (fr) * 2014-07-11 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour traiter une crise vaso-occlusive
ES2749076T3 (es) * 2014-04-30 2020-03-19 Inst Nat Sante Rech Med DNasa para uso en el tratamiento de crisis vaso-oclusivas
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
US12220500B2 (en) * 2018-04-13 2025-02-11 University Of Virginia Patent Foundation Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels
CN109481692A (zh) * 2018-11-30 2019-03-19 东南大学 一种青蒿琥酯肝素衍生物及其药物组合物和应用
US20250205392A1 (en) * 2022-03-29 2025-06-26 The Penn State Research Foundation Device and method for accelerating and guiding vascularization
WO2023215594A1 (fr) 2022-05-05 2023-11-09 Venture Health Studio, Llc Ensemble de distribution d'énergie magnétique
EP4536248A4 (fr) * 2022-06-06 2026-02-11 Ihp Therapeutics Inc Héparine chimiquement modifiée
US20250360161A1 (en) * 2022-06-06 2025-11-27 Ihp Therapeutics Inc. Chemically modified heparin
CN115448994B (zh) * 2022-09-28 2023-08-01 山东大学 一种可中和抗凝低分子量肝素及其制备方法和应用
CN120112299A (zh) 2022-09-29 2025-06-06 爱多拉动物健康公司 用于治疗疼痛和其他医学病症的硫酸化糖胺聚糖及其衍生片段的储存稳定的制剂
GB2625581A (en) 2022-12-21 2024-06-26 Modus Therapeutics Ab New medical use
GB2627263A (en) * 2023-02-17 2024-08-21 Modus Therapeutics Ab New medical use
EP4665360A1 (fr) 2023-02-17 2025-12-24 Modus Therapeutics AB Nouvelle utilisation médicale de l'anuparine dans le traitement de l'endotoxémie
CN116854838A (zh) * 2023-06-30 2023-10-10 重庆望业药物研究有限公司 低分子多糖及其制备方法与应用
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (fr) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Fragments d'heparine ayant une activite anticoagulante selective
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
DE68906345T2 (de) * 1988-10-07 1993-10-28 Hoechst Ag Antimalariazusammenstellungen, gebrauchmachend von Quinidin, Artemisinin und ihren Derivaten.
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
WO1994008595A1 (fr) 1992-10-13 1994-04-28 Virginia Commonwealth University Utilisation d'heparine non anticoagulante dans le traitement des lesions ischemiques et consecutives a une perfusion
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
DE69623840D1 (de) * 1995-03-31 2002-10-31 Hamilton Civic Hospitals Res Zusammensetzung zur Hemmung der Thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
JP3342007B2 (ja) * 1997-11-20 2002-11-05 郁男 山科 低分子ヘパリン修飾体及び皮膚潰瘍治療剤
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6498246B1 (en) 1998-02-26 2002-12-24 Seikagaku Corporation Glycosaminoglycan derivatives and processes for preparing same
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
US6492503B1 (en) * 1998-07-31 2002-12-10 Seikagaku Corporation Glycosaminoglycan and drug compositions containing the same
JP2003504428A (ja) * 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
DE60138115D1 (de) * 2000-09-12 2009-05-07 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20040072796A1 (en) * 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1582531A1 (fr) 2004-03-24 2005-10-05 Aventis Pharma S.A. Procédé d'oxydation d'héparines non-fractionnées et la détection de la présence ou de l'absence de glycosérine dans l'héparine et les produits dérivés de l'héparine.
EP1758557B1 (fr) * 2004-05-11 2011-07-13 Egalet Ltd. Forme galenique gonflant comprenant de la gomme gellane
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
US20070021378A1 (en) * 2005-07-22 2007-01-25 The Regents Of The University Of California Heparin compositions and selectin inhibition
EP1906975A4 (fr) * 2005-07-22 2010-10-06 Trf Pharma Inc Methode destinee a traiter la drepanocytose et les sequelles de la drepanocytose
EP2447285A3 (fr) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Composition d'héparine à faible poids moléculaire et utilisations associées
WO2009007224A1 (fr) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Dérivés d'héparine de faible poids moléculaire ayant une activité neuroprotectrice
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) * 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009073184A1 (fr) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions pour induire le travail et procédés associés
JP5758797B2 (ja) * 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
US20110206770A1 (en) * 2008-07-25 2011-08-25 Alphapharm Pty. Ltd. Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns
US20120183976A1 (en) 2009-04-16 2012-07-19 He Zhou Methods of assessing activity of a polysaccharide composition
AU2010268756A1 (en) * 2009-06-30 2012-01-19 The Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
WO2013095215A1 (fr) 2011-12-19 2013-06-27 Dilaforette Ab Héparines anticoagulantes de faible poids moléculaire
CA2856492C (fr) 2011-12-19 2017-01-10 Dilafor Ab Nouveau glycosaminoglycan faiblement anticoagulant
RU2014143017A (ru) 2012-03-26 2016-05-20 Дилафор Аб Препараты для индукции родов
CA2868479A1 (fr) 2012-03-26 2013-10-03 Dilafor Ab Procede de traitement de l'arret du travail

Also Published As

Publication number Publication date
CY1120194T1 (el) 2018-12-12
HUE037555T2 (hu) 2018-09-28
WO2013095277A1 (fr) 2013-06-27
US9480701B2 (en) 2016-11-01
EP2794667A1 (fr) 2014-10-29
HRP20180725T1 (hr) 2018-06-29
ZA201403654B (en) 2017-08-30
RS57214B1 (sr) 2018-07-31
CN104053675B (zh) 2016-10-12
EP2794666A1 (fr) 2014-10-29
EP2794667B1 (fr) 2018-02-21
CY1120197T1 (el) 2018-12-12
TN2014000237A1 (en) 2015-09-30
DK2794667T3 (en) 2018-04-23
SI2794666T1 (en) 2018-06-29
US9480702B2 (en) 2016-11-01
HK1199893A1 (en) 2015-07-24
ES2669055T3 (es) 2018-05-23
DK2794666T3 (en) 2018-04-23
PL2794667T3 (pl) 2018-09-28
JP2018154848A (ja) 2018-10-04
MX358439B (es) 2018-08-21
IL232903A (en) 2017-02-28
SMT201800218T1 (it) 2018-05-02
WO2013095276A1 (fr) 2013-06-27
JP2015500387A (ja) 2015-01-05
TN2014000236A1 (en) 2015-09-30
IN2014MN01056A (fr) 2015-05-01
CA2856918C (fr) 2017-07-04
SMT201800217T1 (it) 2018-05-02
CA2856477C (fr) 2017-06-27
SI2794667T1 (en) 2018-06-29
US20140364369A1 (en) 2014-12-11
PH12014501387B1 (en) 2014-09-22
JP6703806B2 (ja) 2020-06-03
BR112014014673B1 (pt) 2021-02-17
PT2794667T (pt) 2018-05-16
CA2856918A1 (fr) 2013-06-27
HRP20180726T1 (hr) 2018-06-15
AU2012354226A1 (en) 2014-06-05
MY170069A (en) 2019-07-03
BR112014014673A2 (pt) 2017-06-13
PH12014501387A1 (en) 2014-09-22
CA2856477A1 (fr) 2013-06-27
HK1200471A1 (en) 2015-08-07
MX2014006956A (es) 2014-10-17
US20150031638A1 (en) 2015-01-29
NZ625096A (en) 2016-07-29
EP2794666A4 (fr) 2015-07-22
ES2668273T3 (es) 2018-05-17
PT2794666T (pt) 2018-05-09
RS57213B1 (sr) 2018-07-31
PL2794666T3 (pl) 2018-08-31
HUE037554T2 (hu) 2018-09-28
NO2794667T3 (fr) 2018-07-21
WO2013095215A1 (fr) 2013-06-27
EP2794667A4 (fr) 2015-07-22
AU2012354226B2 (en) 2017-01-12
BR112014014673A8 (pt) 2017-07-04
EP2794666B1 (fr) 2018-02-21
IL232903A0 (en) 2014-07-31
CN104053675A (zh) 2014-09-17

Similar Documents

Publication Publication Date Title
BR112013022641A2 (fr)
BR112013031251A2 (fr)
BR112013027245A2 (fr)
BR112013024383A2 (fr)
BR112013023185A2 (fr)
BR112013022995A2 (fr)
BR112013017670A2 (fr)
BR112013027830A2 (fr)
AP3853A (fr)
BR112013023927A2 (fr)
BR112013027452A2 (fr)
BR112013024365A2 (fr)
BR112013028733A2 (fr)
BR112013027121A2 (fr)
AP2016009466A0 (fr)
BR112013031556A2 (fr)
BR112013026790A2 (fr)
BR112013024588A2 (fr)
BR112013032368A2 (fr)
BR112013032377A2 (fr)
BR112013018949A2 (fr)
NO2794667T3 (fr)
BR112013027761A2 (fr)
BR112013021637A2 (fr)
BR112013025487A2 (fr)